Dialogue Health Technologies Inc.

TSX:CARE Stock Report

Market Cap: CA$346.0m

Dialogue Health Technologies Valuation

Is CARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CARE (CA$5.14) is trading below our estimate of fair value (CA$33.63)

Significantly Below Fair Value: CARE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CARE?

Key metric: As CARE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CARE. This is calculated by dividing CARE's market cap by their current revenue.
What is CARE's PS Ratio?
PS Ratio3.6x
SalesCA$95.88m
Market CapCA$345.99m

Price to Sales Ratio vs Peers

How does CARE's PS Ratio compare to its peers?

The above table shows the PS ratio for CARE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.4x
VMD Viemed Healthcare
1.8x17.8%CA$311.8m
AIDX Healwell AI
10x49.2%CA$251.2m
QIPT Quipt Home Medical
0.4x5.6%CA$145.2m
WELL WELL Health Technologies
1.3x9.3%CA$1.3b
CARE Dialogue Health Technologies
3.6x18.8%CA$346.0m

Price-To-Sales vs Peers: CARE is expensive based on its Price-To-Sales Ratio (3.6x) compared to the peer average (1.3x).

Price to Sales Ratio vs Industry

How does CARE's PS Ratio compare vs other companies in the CA Healthcare Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
DOC CloudMD Software & Services
0.1xn/aUS$7.82m
NPTH NeuPath Health
0.1xn/aUS$6.86m
PHA Premier Health of America
0.05x4.3%US$5.56m
BLMH Bloom Health Partners
0.1xn/aUS$2.85m
CARE 3.6xIndustry Avg. 1.1xNo. of Companies8PS00.61.21.82.43+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CARE is expensive based on its Price-To-Sales Ratio (3.6x) compared to the Canadian Healthcare industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is CARE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CARE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.6x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: CARE is expensive based on its Price-To-Sales Ratio (3.6x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CARE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Nov ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Oct ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Sep ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Aug ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Jul ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Jun ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
May ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Apr ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Mar ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Feb ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Jan ’25n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Dec ’24n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Nov ’24n/a
CA$4.93
0%
6.2%CA$5.15CA$4.50n/a3
Oct ’24CA$5.13
CA$5.04
-1.7%
4.8%CA$5.15CA$4.50n/a6
Sep ’24CA$5.11
CA$5.04
-1.2%
4.8%CA$5.15CA$4.50n/a6
Aug ’24CA$5.07
CA$5.04
-0.6%
4.8%CA$5.15CA$4.50n/a6
Jul ’24CA$3.10
CA$4.91
+58.5%
16.6%CA$6.25CA$4.00n/a8
Jun ’24CA$3.34
CA$5.06
+51.5%
17.3%CA$6.25CA$4.00n/a9
May ’24CA$3.49
CA$5.03
+44.2%
17.3%CA$6.25CA$4.00n/a9
Apr ’24CA$3.59
CA$5.03
+40.2%
17.3%CA$6.25CA$4.00n/a9
Mar ’24CA$3.66
CA$4.89
+33.6%
21.3%CA$6.25CA$3.25n/a9
Feb ’24CA$3.84
CA$4.95
+28.9%
20.3%CA$6.25CA$3.25n/a10
Jan ’24CA$2.32
CA$4.88
+110.1%
23.5%CA$6.25CA$2.50n/a10
Dec ’23CA$2.83
CA$5.03
+77.6%
20.7%CA$6.75CA$3.50n/a10
Nov ’23CA$2.65
CA$5.80
+118.9%
29.7%CA$8.50CA$3.50n/a10

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

NeuPath Health

CA$9.6m

Provides chronic pain management services in Canada.

NPTH

CA$0.17

7D

3.0%

1Y

9.7%

Andlauer Healthcare Group

CA$1.7b

A supply chain management company, provides a platform of customized third-party logistics (3PL) and specialized transportation solutions for the healthcare sector in Canada and the United States.

AND

CA$42.64

7D

-0.8%

1Y

9.6%

Hamilton Thorne

CA$346.3m

Develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets.

HTL

CA$2.24

7D

0.4%

1Y

77.8%